Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ILK | Q13418 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106441 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31731285 | 0.98 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL2171446 | 0.90 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL1849993 | 0.85 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL906835 | 0.84 | HTT (0.61) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| 2-Mercaptobenzothiazole SCHEMBL2170236 | 0.82 | MAPT (0.49) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL2170238 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL28090972 | 0.79 | CA2 (0.56) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL92781 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| Bromide SCHEMBL10996884 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539841-A2 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| EP-4441112-A1 | METHOD OF UNDERWATER BONDING | Henkel AG & Co. KGaA (DE) | 2024-10-09 | — | — | EP | claimed |
| US-20240318052-A1 | METHOD OF UNDERWATER BONDING | HENKEL AG & CO KGAA (DE) | 2024-09-26 | — | — | US | claimed |
| CN-118355041-A | Method for underwater bonding | 汉高股份有限及两合公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2023244996-A2 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023099777-A1 | METHOD OF UNDERWATER BONDING | Henkel IP & Holding GmbH (DE) | 2023-06-08 | — | — | WO | claimed |
| EP-3464446-B1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2021-06-23 | — | — | EP | claimed |
| CN-109476874-B | Two-part cyanoacrylate curable adhesive systems | 汉高知识产权控股有限责任公司 | 2021-04-16 | — | — | CN | claimed |
| EP-3464446-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2019-04-10 | — | — | EP | claimed |
| US-10100235-B2 | Two-part cyanoacrylate curable adhesive system | Henkel IP & Holding GmbH (DE) | 2018-10-16 | — | — | US | claimed |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | claimed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | claimed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | claimed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | claimed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | claimed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | claimed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | claimed |
| US-6225275-B1 | ACTIVATION OF OXIDOREDUCTASES FOR BLEACHING FABRICS DURING WASHING | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. | 2001-05-01 | — | — | US | claimed |
| EP-0975740-A1 | METHOD FOR ENHANCING THE ACTIVITY OF AN ENZYME, BLEACH COMPOSITION, DETERGENT COMPOSITION AND PROCESS FOR INHIBITING DYE TRANSFER | UNILEVER N.V. (NL) | 2000-02-02 | — | — | EP | claimed |
| WO-1998056899-A1 | METHOD FOR ENHANCING THE ACTIVITY OF AN ENZYME, BLEACH COMPOSITION, DETERGENT COMPOSITION AND PROCESS FOR INHIBITING DYE TRANSFER | UNILEVER N.V. (NL) | 1998-12-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP10 | SMN1; SMN2 1161/4885NPC1 3790/4885RAB9A 1953/4885 |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP3 | SMN1; SMN2 1072/4885NPC1 4248/4885RAB9A 1032/4885 |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | SMN1; SMN2 1161/4885NPC1 3790/4885RAB9A 1953/4885 |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP1, MMP13 | SMN1; SMN2 1173/4885NPC1 3989/4885RAB9A 727/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | SMN1; SMN2 1161/4885NPC1 3790/4885RAB9A 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.